Exact Mass: 415.182
Exact Mass Matches: 415.182
Found 150 metabolites which its exact mass value is equals to given mass value 415.182,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Mavelertinib
Mavelertinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Rupatadine
13-chloro-2-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaene
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Rupatadine is a second-generation tricyclic H1-antihistamine.
4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-
22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.0^{1,13}.0^{2,21}.0^{4,12}.0^{5,10}.0^{19,25}]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
CID 9844747
4-fluoro-N-(2-{4-[2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects[1][2][3].
Sabeluzole
1-{4-[(1,3-benzothiazol-2-yl)(methyl)amino]piperidin-1-yl}-3-(4-fluorophenoxy)propan-2-ol
C26170 - Protective Agent > C1509 - Neuroprotective Agent
(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-(4-hydroxyphenyl)Propanoic acid
(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-(4-hydroxyphenyl)Propanoic acid
Gly Gly Pro Trp
(2S)-2-{[(2S)-1-[2-(2-aminoacetamido)acetyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanoic acid
Gly Gly Trp Pro
(2S)-1-[(2S)-2-[2-(2-aminoacetamido)acetamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid
Gly Pro Gly Trp
(2S)-2-(2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}acetamido)-3-(1H-indol-3-yl)propanoic acid
Gly Pro Trp Gly
2-[(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanamido]acetic acid
Gly Trp Gly Pro
(2S)-1-{2-[(2S)-2-(2-aminoacetamido)-3-(1H-indol-3-yl)propanamido]acetyl}pyrrolidine-2-carboxylic acid
Gly Trp Pro Gly
2-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}acetic acid
Pro Gly Gly Trp
(2S)-3-(1H-indol-3-yl)-2-(2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}acetamido)propanoic acid
Pro Gly Trp Gly
2-[(2S)-3-(1H-indol-3-yl)-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]acetic acid
Pro Trp Gly Gly
2-{2-[(2S)-3-(1H-indol-3-yl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]acetamido}acetic acid
Trp Gly Gly Pro
(2S)-1-(2-{2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]acetamido}acetyl)pyrrolidine-2-carboxylic acid
Trp Gly Pro Gly
2-{[(2S)-1-{2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]acetyl}pyrrolidin-2-yl]formamido}acetic acid
Trp Pro Gly Gly
2-(2-{[(2S)-1-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}acetamido)acetic acid
Donepezil Hydrochloride
Donepezil Hydrochloride
D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D002491 - Central Nervous System Agents > D018697 - Nootropic Agents C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors
Benzeneethanol, 4-[1-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-1-methylethyl]-, 4-methylbenzenesulfonate (ester)
Benzeneethanol, 4-[1-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-1-methylethyl]-, 4-methylbenzenesulfonate (ester)
(S)-2-TERT-BUTOXYCARBONYLAMINO-3-[4-(DIETHOXY-PHOSPHORYLMETHYL)-PHENYL]-PROPIONIC ACID
(S)-2-TERT-BUTOXYCARBONYLAMINO-3-[4-(DIETHOXY-PHOSPHORYLMETHYL)-PHENYL]-PROPIONIC ACID
(S)-3-(4-ACETYLPHENYL)-4-ISOPROPYLOXAZOLIDIN-2-ONE
(S)-3-(4-ACETYLPHENYL)-4-ISOPROPYLOXAZOLIDIN-2-ONE
Coelenterazine cp
8-(cyclopentylmethyl)-6-(4-hydroxyphenyl)-2-[(4-hydroxyphenyl)methyl]-7H-imidazo[1,2-a]pyrazin-3-one
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-phenyl-N-(3-pyridinylmethyl)- (9CI)
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-phenyl-N-(3-pyridinylmethyl)- (9CI)
methyl 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)ethylidene]-1,3,3-trimethylindoline-5-carboxylate
methyl 2-[(1,5-dihydro-3-methyl-5-oxo-1-phenyl-4H-pyrazol-4-ylidene)ethylidene]-1,3,3-trimethylindoline-5-carboxylate
3-ethynyl-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
3-ethynyl-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine
N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine
ML228 (CID-46742353) is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF[1][2].
1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine Maleate
1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine Maleate
5-[[4-(2-Amino-2-oxoethoxy)-3-methoxyphenyl]methylamino]-2-(4-morpholinyl)benzoic acid
5-[[4-(2-Amino-2-oxoethoxy)-3-methoxyphenyl]methylamino]-2-(4-morpholinyl)benzoic acid
4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine
4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine
(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
Rupatadine
Rupatadine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
N-[4-(4-methylphenoxy)phenyl]-2-[2-(2-oxopyrrolidin-1-yl)anilino]acetamide
N-[4-(4-methylphenoxy)phenyl]-2-[2-(2-oxopyrrolidin-1-yl)anilino]acetamide
4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-
22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.0^{1,13}.0^{2,21}.0^{4,12}.0^{5,10}.0^{19,25}]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol
(10S,12S)-3-acetyl-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.02,10.04,9.015,20]henicosa-4,6,8,15,17,19-hexaene-13,21-dione
(10S,12S)-3-acetyl-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.02,10.04,9.015,20]henicosa-4,6,8,15,17,19-hexaene-13,21-dione
6-phenyl-N-[(3-phenylphenyl)methyl]-3-(2-pyridinyl)-1,2,4-triazin-5-amine
6-phenyl-N-[(3-phenylphenyl)methyl]-3-(2-pyridinyl)-1,2,4-triazin-5-amine
(3S,3aR,8aS,8bS)-5-ethyl-2-(phenylmethyl)spiro[1H-indole-3,4-3a,6,7,8,8a,8b-hexahydropyrrolo[3,4-a]pyrrolizine]-1,2,3-trione
(3S,3aR,8aS,8bS)-5-ethyl-2-(phenylmethyl)spiro[1H-indole-3,4-3a,6,7,8,8a,8b-hexahydropyrrolo[3,4-a]pyrrolizine]-1,2,3-trione
[2-(2,5-dimethylanilino)-2-oxoethyl] (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoate
[2-(2,5-dimethylanilino)-2-oxoethyl] (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoate
1-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]ethanone
1-(5,6-Dihydrobenzo[b][1]benzazepin-11-yl)-2-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]ethanone
2-[(2R,5R,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2R,5R,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5S,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5S,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
[(1R,2aR,8bR)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1R,2aR,8bR)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aR,8bR)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aR,8bR)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
4-[4-[(2S,3R)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
4-[4-[(2S,3R)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
4-[4-[(2R,3R)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
4-[4-[(2R,3R)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
2-[(2R,5S,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2R,5S,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5R,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5R,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5S,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5S,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2R,5R,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2R,5R,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2R,5S,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2R,5S,6S)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5R,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-[(2S,5R,6R)-5-[[(2-fluoroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-(phenylmethyl)acetamide
2-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
2-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[1-oxo-2-(2-pyridinyl)ethyl]amino]ethyl]-3-oxanyl]benzamide
[(1R,2aS,8bS)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1R,2aS,8bS)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(2-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-(3-pyridinyl)methanone
[(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-pyridin-4-ylmethanone
[(1S,2aS,8bS)-1-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-4-yl]-pyridin-4-ylmethanone
4-[4-[(2S,3S)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
4-[4-[(2S,3S)-1-acetyl-6-[cyclopropyl(oxo)methyl]-2-(hydroxymethyl)-1,6-diazaspiro[3.3]heptan-3-yl]phenyl]benzonitrile
ALM301
ALM301
ALM301 is an orally active highly specific AKT inhibitor with IC50 values of 0.13 μM, 0.09 μM and 2.75 μM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth[1].
BC1618
BC1618
BC1618, an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation). BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity[1].
3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
12-hydroxy-9-methoxy-10,22-dimethyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0²,⁶.0³,²¹.0⁷,¹².0¹⁴,¹⁸.0¹⁹,²³]tricosa-6,9-diene-8,11-dione
12-hydroxy-9-methoxy-10,22-dimethyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0²,⁶.0³,²¹.0⁷,¹².0¹⁴,¹⁸.0¹⁹,²³]tricosa-6,9-diene-8,11-dione
(3'ar,6'as)-2'-hydroxy-3,5-dimethoxy-3'a-[(4-methoxyphenyl)methyl]-6'a-(methylamino)-3',6'-dihydrospiro[cyclohexane-1,5'-furo[2,3-d]imidazole]-2,5-dien-4-one
(3'ar,6'as)-2'-hydroxy-3,5-dimethoxy-3'a-[(4-methoxyphenyl)methyl]-6'a-(methylamino)-3',6'-dihydrospiro[cyclohexane-1,5'-furo[2,3-d]imidazole]-2,5-dien-4-one
(2s,10s,12s)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2s,10s,12s)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,10r,12r)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,10r,12r)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(1r,3r,12s,13s,18s,19s,21r,23r)-12-hydroxy-9-methoxy-10,22-dimethyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0²,⁶.0³,²¹.0⁷,¹².0¹⁴,¹⁸.0¹⁹,²³]tricosa-6,9-diene-8,11-dione
(1r,3r,12s,13s,18s,19s,21r,23r)-12-hydroxy-9-methoxy-10,22-dimethyl-4,17-dioxa-2,14,22-triazaheptacyclo[11.10.0.0²,⁶.0³,²¹.0⁷,¹².0¹⁴,¹⁸.0¹⁹,²³]tricosa-6,9-diene-8,11-dione
(2s,10s,12r)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2s,10s,12r)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,10r,12s)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,10r,12s)-3-acetyl-13-hydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[1-(hydroxymethyl)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-5-yl]oxy}oxane-3,4,5-triol
(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[1-(hydroxymethyl)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-5-yl]oxy}oxane-3,4,5-triol
